Ongoing trials
| Clinical Study | Principal Investigator |
|---|---|
|
Protocol No: CR187-18
A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®- EU in combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumb alone during the Maintenance phase in patients with newly diagnosed or recurrent stage IIIB/IV Non Squamous (ns) Non Small Cell Lung Cancer (NSCLC). |
Dr. Praveena Voonna
|
|
Protocol No: CA-170-302
A Phase IIb/III, Randomised, Double-blind, Placebo-controlled, Multicentre, Study of CA-170 in Combination with Chemotherapy in Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer (ASIAD-3) |
Dr. Rajani Priya Yedla |
|
Protocol No: ODM-203-201
A Phase II Open-Label Trial Evaluating the Efficacy and Safety of Once Daily Oral ODM-203 in Patients with Unresectable Transitional Cell Urothelial Carcinoma with FGFR3 Mutation (TEJAS-1) |
Dr. Kota Kishore Kumar |
|
Protocol No. 0063-17
Study Title: A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy. |
Dr. Praveena Voonna
|
|
Protocol No. 1045-18
Study Title: A phase III, two arm, multi centric, randomized, open label, parallel study to compare pharmacodynamics of Goserelin 10.8 mg Injection (Eurofarma Laboratórios S.A) administered subcutaneously with the reference drug ZOLADEX® 10.8 mg Injection (AstraZeneca) in patients with advanced prostate cancer.
|
Dr. Kota Kishore Kumar |
|
Protocol No. 1046-18
Study Title: A phase III, two arm, multicentric, randomized, open label, parallel, multiple dose pharmacodynamic study of Goserelin 3.6mg Injection (Eurofarma Laboratorios S. A.) administered subcutaneously in comparison with the reference drug ZOLADEX® 3.6 mg Injection (AstraZeneca) administered subcutaneously in premenopausal patients with advanced Breast cancer.
|
Dr. Praveena Voonna |
|
Protocol No: CRD48
An open-label, balanced, randomized, multiple-dose, steady state, two-treatment, two-sequence,
full replicate, four-period, bioequivalence study of Olaparib Tablet 150 mg, manufactured by
M/s Genvion Corporation, Canada for M/s Cipla Ltd., India and LYNPARZA® (Olaparib
Tablet) 150 mg of AstraZeneca Pharmaceuticals LP Wilmington, DE in patients with either
ovarian cancer or breast cancer or pancreatic cancer or prostate cancer who are eligible to
receive Olaparib under fasting conditions. |
Dr. Praveena Voonna
|
|
Protocol No: (NIVO.22.001)
A Phase III, Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel-group,
Study to Investigate the Efficacy, Safety, and Pharmacokinetics of ZRC-3276 Versus Opdivo®
(Nivolumab) in Subject with locally advanced or Metastatic Non-Small Cell Lung Cancer |
Dr. Rajani Priya Yedla |
|
Protocol No: 0375-20
A Randomized, Double-Blind, Multicenter, Parallel Group, Clinical Trial to Compare Efficacy,
Safety and Immunogenicity of Intas Pertuzumab with Perjeta® (In combination with
Trastuzumab and Docetaxel) in Patients with HER2-Positive Metastatic Breast Cancer. |
Dr. Praveena Voonna |
